Govorkova EA - Search Results

1

Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.

Reddy MB, Yang KH, Rao G, Rayner CR, Nie J, Pamulapati C, Marathe BM, Forrest A, Govorkova EA. Reddy MB, et al. Among authors: govorkova ea. PLoS One. 2015 Oct 13;10(10):e0138069. doi: 10.1371/journal.pone.0138069. eCollection 2015. PLoS One. 2015. PMID: 26460484 Free PMC article.

2

Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.

Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Govorkova EA, et al. Antimicrob Agents Chemother. 2001 Oct;45(10):2723-32. doi: 10.1128/AAC.45.10.2723-2732.2001. Antimicrob Agents Chemother. 2001. PMID: 11557461 Free PMC article.

3

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

Yen HL, Monto AS, Webster RG, Govorkova EA. Yen HL, et al. Among authors: govorkova ea. J Infect Dis. 2005 Aug 15;192(4):665-72. doi: 10.1086/432008. Epub 2005 Jul 15. J Infect Dis. 2005. PMID: 16028136

4

Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.

Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. Govorkova EA, et al. Antimicrob Agents Chemother. 2007 Apr;51(4):1414-24. doi: 10.1128/AAC.01312-06. Epub 2007 Feb 12. Antimicrob Agents Chemother. 2007. PMID: 17296744 Free PMC article.

5

Inefficient transmission of H5N1 influenza viruses in a ferret contact model.

Yen HL, Lipatov AS, Ilyushina NA, Govorkova EA, Franks J, Yilmaz N, Douglas A, Hay A, Krauss S, Rehg JE, Hoffmann E, Webster RG. Yen HL, et al. Among authors: govorkova ea. J Virol. 2007 Jul;81(13):6890-8. doi: 10.1128/JVI.00170-07. Epub 2007 Apr 25. J Virol. 2007. PMID: 17459930 Free PMC article.

6

Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.

Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA. Ilyushina NA, et al. Among authors: govorkova ea. Antivir Ther. 2007;12(3):363-70. Antivir Ther. 2007. PMID: 17591026

7

Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.

Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. Yen HL, et al. Among authors: govorkova ea. J Virol. 2007 Nov;81(22):12418-26. doi: 10.1128/JVI.01067-07. Epub 2007 Sep 12. J Virol. 2007. PMID: 17855542 Free PMC article.

8

Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.

Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG. Ilyushina NA, et al. Among authors: govorkova ea. PLoS Pathog. 2008 Apr 11;4(4):e1000043. doi: 10.1371/journal.ppat.1000043. PLoS Pathog. 2008. PMID: 18404209 Free PMC article.

9

Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.

Boltz DA, Rehg JE, McClaren J, Webster RG, Govorkova EA. Boltz DA, et al. Among authors: govorkova ea. J Infect Dis. 2008 May 1;197(9):1315-23. doi: 10.1086/586711. J Infect Dis. 2008. PMID: 18422444

10

Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.

Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. Ilyushina NA, et al. Among authors: govorkova ea. Antimicrob Agents Chemother. 2008 Nov;52(11):3889-97. doi: 10.1128/AAC.01579-07. Epub 2008 Aug 25. Antimicrob Agents Chemother. 2008. PMID: 18725448 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters